Au Revoir '98: Our Top Ten List
From device companies that merged to drug companies that didn't, big drugs that paid off big and small-cap stocks that paid off small, 1998 was a newshound's delight in the health care products industry. Here's a baker's dozen of the top news stories in health care in 1998.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.